APA (7th ed.) Citation

Kemp, R., & Prasad, V. (2017). Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Medicine, 15, 1. https://doi.org/10.1186/s12916-017-0902-9

Chicago Style (17th ed.) Citation

Kemp, Robert, and Vinay Prasad. "Surrogate Endpoints in Oncology: When Are They Acceptable for Regulatory and Clinical Decisions, and Are They Currently Overused?" BMC Medicine 15 (2017): 1. https://doi.org/10.1186/s12916-017-0902-9.

MLA (9th ed.) Citation

Kemp, Robert, and Vinay Prasad. "Surrogate Endpoints in Oncology: When Are They Acceptable for Regulatory and Clinical Decisions, and Are They Currently Overused?" BMC Medicine, vol. 15, 2017, p. 1, https://doi.org/10.1186/s12916-017-0902-9.